ClinicalTrials.Veeva
Menu

Find clinical trials for Lymphoma in Taipei City

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Leukemia
Non-Hodgkin Lymphoma
Lymphoid Leukemia
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Taipei City, TWN:

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)

focused on patients who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come bac...

Enrolling
Marginal Zone Lymphoma (MZL)
Relapsed/Refractory Follicular Lymphoma
Drug: Rituximab
Drug: Lenalidomide

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Taipei City, Taiwan and 80 other locations

of CHO-H01 in subjects with relapsed/refractory CD20+ non-Hodgkin's lymphoma. It will also determine maximum tolerated dose (MTD) and recomm...

Enrolling
Non-Hodgkin Lymphoma
Biological: CHO-H01

Phase 1, Phase 2

Cho Pharma

Taipei, Taiwan and 7 other locations

The primary objective of this study is to determine the recommended dosing regimen of loncastuximab tesirine in diffuse large B-cell lymphoma...

Enrolling
High-grade B-cell Lymphoma
Diffuse Large B-Cell Lymphoma
Drug: Loncastuximab Tesirine

Phase 1

ADC Therapeutics

Taipei, Taiwan and 12 other locations

This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma...

Active, not recruiting
Relapsed/Refractory Peripheral T-Cell Lymphoma
Adult T Cell Leukemia/Lymphoma
Drug: Valemetostat Tosylate

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Taipei, Taiwan and 59 other locations

A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas...

Enrolling
EBV Associated Lymphoma
EBV Related Non-Hodgkin's Lymphoma
Drug: Nanatinostat in combination with valganciclovir

Phase 2

Viracta Therapeutics

Taipei City, Taiwan and 93 other locations

Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)

Phase 3

Novartis
Novartis

Taipei, Taiwan and 66 other locations

treatment of advanced classical Hodgkin lymphoma(HL)...

Active, not recruiting
Hodgkin Lymphoma
Drug: brentuximab vedotin
Drug: bleomycin

Phase 3

Takeda
Takeda

Taipei, Taiwan and 215 other locations

to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma...

Begins enrollment in 1 month
Lymphoma, Follicular
Drug: Golcadomide
Drug: Doxorubicin

Phase 2

Celgene
Celgene

Taipei, Taiwan and 64 other locations

pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-0201 in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma...

Enrolling
B-cell Non Hodgkin Lymphoma
Drug: DR-0201

Phase 1

Dren Bio

Taipei, Taiwan and 7 other locations

or obinutuzumab) in subjects with relapsed or refractory (R/R) lymphoma. Subjects must have received at least 2 prior lines of therapy, and ...

Active, not recruiting
Lymphoma
Drug: Rituximab
Drug: CC-220

Phase 1

Celgene
Celgene

Taoyuan City, Taiwan and 25 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems